•  

Posts Tagged: business development examples

Bioprinter covered on CTV’s Canada AM

The Bioprinter project, a three-way initiative from MaRS Innovation, the University of Toronto and Sunnybrook Health Sciences Centre, was featured on Canada AM on January 29 during a segment with Dr. Marla Shapiro, the program's Health and Medical Expert. The Bioprinter, whose commercial applications are being developed by MI's Fanny Sie, is a 3D printer than can print on organic material, including skin. Click here to watch the full segment on CTV's Canada AM.  Shapiro visited Dr. Marc Jeschke and his team in his lab at Sunnybrook to ... Read more

WaveCheck to Transform Chemotherapy Monitoring for Women with Breast Cancer

Indiegogo campaign to raise funds for North American clinical study during Breast Cancer Awareness Month; 12 artists donate 13 original works worth over $15,000 to support campaign Toronto, Canada (October 9, 2013) — WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer ... Read more

Bringing mad science to mass production: Financial Post features the Bio Printer project

“It’s one thing to invent a machine that prints skin, but it’s a whole other challenge to bring what seems like the domain of mad science to mass production,” Matthew Braga wrote in  "Looking for ways to get 'skin' in the game," published in the Financial Post on July 15. The article focuses on MaRS Innovation's (MI) and the Innovations and Partnerships Office's (University of Toronto) joint efforts to commercialize the bio printer, a "prototype 3D printer that, instead of extruding layers ... Read more

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as ... Read more

Shotlst: “Track changes” for the physical world

Shotlst is one of six inaugural UTEST companies; next UTEST application round to begin shortly What if you could turn on Microsoft Word’s “track changes” tool and apply it at will to the world around you? Sound like science fiction? Meet Matt Ratto, a professor in the University of T’s Faculty of Information, and Mike Borg, a recent graduate of the faculty. They’ve formed Shotlst, a new software company being incubated by the University of Toronto Early Stage Technology (UTEST) program. The central metaphor of ... Read more

VitalHub’s Chart Makes Apple’s Top 80 List of Doctor Apps

VitalHub Chart has been named to Apple's list of top 80 apps for doctors, nurses, patients and healthcare professionals in the "EMR and patient monitoring" category. Here's a description of the app, which is made by Toronto-based VitalHub Corp., from the Apple list curators: “VitalHub Chart puts patient data at your fingertips. You can access the information you need any time, anywhere there is WiFi or cellular service. No more waiting for a free desktop, hunting for a workstation on wheels, or carrying printouts ... Read more

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects. “Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, director, OICR’s Medicinal Chemistry Platform. “OICR is proud to ... Read more